Genmab AS - Company Profile
Powered by 
All the data and insights you need on Genmab AS in one report.
$295
- Save hours of research time and resources with
our up-to-date Genmab AS Strategy Report
- Understand Genmab AS position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Genmab AS Catalyst Calendar
Proactively evaluate Genmab AS’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Genmab AS Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 30 Sep 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 29 Sep 2019 | Phase I/II Trial Results | Belgian Gynaecological Oncology Group; Genmab AS; GOG Foundation Inc; Merck & Co Inc; Seagen Inc; The European Network of Gynaecological Oncological Trial Groups | GMAB; MRK; SGEN | pembrolizumab; tisotumab vedotin | Oncology | Cervical Cancer | Company Press Release |
| 08 Sep 2019 | Phase I/II Trial Results | Genmab AS | GMAB | enapotamab vedotin | Oncology | Anaplastic Thyroid Cancer; Cervical Cancer; Endometrial Cancer; Melanoma; Non-Small Cell Lung Cancer; Ovarian Cancer; Sarcomas; Solid Tumor; Thyroid Cancer | Company Press Release |
| 01 Sep 2019 | Phase III Trial Completion | Genmab AS; Novartis AG | GMAB; NOVN | Kesimpta | Central Nervous System | Multiple Sclerosis; Relapsing Multiple Sclerosis (RMS); Relapsing Remitting Multiple Sclerosis (RRMS); Secondary Progressive Multiple Sclerosis (SPMS) | Company Press Release |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer